{"disease":{"id":"mcrpc","name":"mcrpc"},"drugs":{"marketed":[{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"abiraterone","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone","indication_name":"Chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"talzenna","indication_name":"HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"rucaparib","indication_name":"Treatment of BRCA-mutated mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."},{"drug_id":"lutetium-lu-177-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","company_name":"","drug_phase":"marketed","molecular_target":"PSMA","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Lutetium Lu 177 vipivotide tetraxetan binds to PSMA on prostate cancer cells, delivering radiation that causes DNA damage and cell death."},{"drug_id":"chembl-chembl1094636","indication_name":"BRCA-mutated mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NIRAPARIB","company_name":"","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, CYP17","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Niraparib inhibits PARP enzymes, causing DNA damage and cell death, while abiraterone inhibits CYP17, reducing androgen production."}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06136650","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03453528","title":"Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1225,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT04516161","title":"EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)","phase":"","overall_status":"COMPLETED","enrollment_count":1180,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05701007","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","phase":"","overall_status":"COMPLETED","enrollment_count":1083,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03395197","title":"Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1054,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04597125","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06551324","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04691804","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":496,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03460977","title":"A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":453,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT01977651","title":"A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06134232","title":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Dendreon","has_results":false},{"nct_id":"NCT06768255","title":"Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Ding-Wei Ye","has_results":false},{"nct_id":"NCT03896984","title":"Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).","phase":"","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03972657","title":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04712890","title":"Determination of Prevalence and Features of HRRm mCRPC (ADAM)","phase":"","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06702995","title":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":307,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT06785636","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Pathos AI, Inc.","has_results":false},{"nct_id":"NCT06830408","title":"Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT07570966","title":"Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":217,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03480646","title":"ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":true},{"nct_id":"NCT05032040","title":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07226986","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":123,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03939689","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Progenics Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06001255","title":"ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT04015622","title":"PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT06720532","title":"Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hannah Schaefer","has_results":false},{"nct_id":"NCT05547061","title":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":91,"lead_sponsor_name":"Cellbion Co., Ltd.","has_results":false},{"nct_id":"NCT05413850","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":82,"lead_sponsor_name":"Blue Earth Therapeutics Ltd","has_results":false},{"nct_id":"NCT07214961","title":"Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"ARTBIO Inc.","has_results":false},{"nct_id":"NCT06344715","title":"Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"SL VAXiGEN","has_results":false},{"nct_id":"NCT04862091","title":"Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06801236","title":"Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Acerand Therapeutics (Hong Kong) Limited","has_results":false},{"nct_id":"NCT07451795","title":"SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03724747","title":"Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05658003","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05670106","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03899467","title":"The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":true},{"nct_id":"NCT06659926","title":"The Radium-select Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT04089553","title":"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07310355","title":"68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Chengdu StarRay Therapeutics Co., Ltd","has_results":false},{"nct_id":"NCT05425862","title":"Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":48,"lead_sponsor_name":"Peter MacCallum Cancer Centre, Australia","has_results":false},{"nct_id":"NCT07533708","title":"A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT07302763","title":"Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity","phase":"NA","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Frederic Pouliot","has_results":false},{"nct_id":"NCT02826772","title":"Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Suzhou Kintor Pharmaceutical Inc,","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}